B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Phase 2 Completed 216 enrolled Novartis Vaccines Novartis · collab

RandomizedParallel-groupOpen-labelPrevention

Summary

This study is aimed to assess whether the frequency of meningococcal serogroup A, C, W-135 and Y specific memory B Cells, measured 1 month after a primary vaccination series of Novartis MenACWY vaccine, predicts the specific serum bactericidal activity using human complement (hSBA) of (respectively) serogroup A, C, W-135 and Y at 12 months of age

Timeline

Start: 2007-07
Primary completion: 2009-05
Completion: 2009-06

Publications

Results Blanchard-Rohner G, Snape MD, Kelly DF, O'Connor D, John T, Clutterbuck EA, Ohene-Kena B, Klinger CL, Odrljin T, Pollard AJ. The B-cell response to a primary and booster course of MenACWY-CRM(1)(9)(7) vaccine administered at 2, 4 and 12 months of age. Vaccine. 2013 May 7;31(20):2441-8. doi: 10.1016/j.vaccine.2013.03.036. Epub 2013 Apr 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Menveo	Vaccine	0.5 ml	Intramuscular
Background	DTaP-Hib-IPV	Vaccine	0.5 ml	Intramuscular
Background	Heptavalent Streptoccus pneumonia; Prevnar	Unknown	0.5 ml	Intramuscular
Background	Hib	Vaccine	0.5 ml	Intramuscular
Background	Measles, mumps, and rubella vaccine; Priorix	Vaccine	0.5 ml	Intramuscular

B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants

Summary

Timeline

Publications

Drugs

Indications